[{"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4495564", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "Compound repurposing is an important strategy being pursued in the identification of effective treatment against the SARS-CoV-2 infection and COVID-19 disease. In this regard, SARS-CoV-2 main protease (M-Pro), also termed 3CL-Pro, is an attractive drug target as it plays a central role in viral replication by processing the viral polyprotein into 11 non-structural proteins. We report the results of a screening campaign involving ca 8.7 K compounds containing marketed drugs, clinical and preclinical candidates, and chemicals regarded as safe in humans. We confirmed previously reported inhibitors of 3CL-Pro, but we have also identified 68 compounds with IC50 lower than 1 uM and 127 compounds with IC50 lower than 5 uM. Profiling showed 67% of confirmed hits were selective (> 5 fold) against other Cys- and Ser- proteases (Chymotrypsin and Cathepsin-L) and MERS 3CL-Pro. Selected compounds were also analysed in their binding characteristics.", "title": "Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4495564", "journal_full_title": null, "_metadata": {"related_activities": {"count": 9029}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 7219}, "related_targets": {"count": 3}}, "doi": "10.6019/CHEMBL4495564", "authors": "Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4495565", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "Worldwide, there are intensive efforts to identify repurposed drugs as potential therapies against SARS-CoV-2 infection and the associated COVID-19 disease. To date, the anti-inflammatory drug dexamethasone and (to a lesser extent) the RNA-polymerase inhibitor remdesivir have been shown to be effective in reducing mortality and patient time to recovery, respectively, in patients. Here, we report the results of a phenotypic screening campaign within an EU-funded project (H2020-EXSCALATE4COV) aimed at extending the repertoire of anti-COVID therapeutics through repurposing of available compounds and highlighting compounds with new mechanisms of action against viral infection. We screened 8702 molecules from different repurposing libraries, to reveal 110 compounds with an anti-cytopathic IC50 < 20 \u00b5M. From this group, 18 with a safety index greater than 2 are also marketed drugs, making them suitable for further study as potential therapies against COVID-19. Our result supports the idea that a systematic approach to repurposing is a valid strategy to accelerate the necessary drug discovery process.", "title": "Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4495565", "journal_full_title": null, "_metadata": {"related_activities": {"count": 9179}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 7219}, "related_targets": {"count": 3}}, "doi": "10.6019/CHEMBL4495565", "authors": "Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4303087", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "SARS-CoV-2 emerged in China at the end of 2019 and has rapidly become a pandemic with roughly 2.7 million recorded COVID-19 cases and greater than 189,000 recorded deaths by April 23rd, 2020 (www.WHO.org). There are no FDA approved antivirals or vaccines for any coronavirus, including SARS-CoV-2. Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA approved drugs. Rapid development and human testing of potential antivirals is greatly needed. A quick way to test compounds with potential antiviral activity is through drug repurposing. Numerous drugs are already approved for human use and subsequently there is a good understanding of their safety profiles and potential side effects, making them easier to fast-track to clinical studies in COVID-19 patients. Here, we present data on the antiviral activity of 20 FDA approved drugs against SARS-CoV-2 that also inhibit SARS- CoV and MERS-CoV. We found that 17 of these inhibit SARS-CoV-2 at a range of IC50 values at non-cytotoxic concentrations. We directly follow up with seven of these to demonstrate all are capable of inhibiting infectious SARS-CoV-2 production. Moreover, we have evaluated two of these, chloroquine and chlorpromazine, in vivo using a mouse-adapted SARS-CoV model and found both drugs protect mice from clinical disease.", "title": "Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4303087", "journal_full_title": null, "_metadata": {"related_activities": {"count": 142}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 19}, "related_targets": {"count": 4}}, "doi": "10.1101/2020.03.25.008482", "authors": "Stuart Weston, Christopher M. Coleman, Rob Haupt, James Logue, Krystal Matthews and Matthew B. Frieman"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4303097", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "A novel coronavirus, named SARS-CoV-2, emerged in 2019 from Hubei region in China and rapidly spread worldwide. As no approved therapeutics exists to treat Covid-19, the disease associated to SARS-Cov-2, there is an urgent need to propose molecules that could quickly enter into clinics. Repurposing of approved drugs is a strategy that can bypass the time consuming stages of drug development. In this study, we screened the Prestwick Chemical Library\u00ae composed of 1,520 approved drugs in an infected cell-based assay. 90 compounds were identified. The robustness of the screen was assessed by the identification of drugs, such as Chloroquine derivatives and protease inhibitors, already in clinical trials. The hits were sorted according to their chemical composition and their known therapeutic effect, then EC50 and CC50 were determined for a subset of compounds. Several drugs, such as Azithromycine, Opipramol, Quinidine or Omeprazol present antiviral potency with 2<EC50<20\u00b5M. By providing new information on molecules inhibiting SARS-CoV-2 replication in vitro, this study could contribute to the short-term repurposing of drugs against Covid-19.", "title": "In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4303097", "journal_full_title": null, "_metadata": {"related_activities": {"count": 1571}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 1520}, "related_targets": {"count": 3}}, "doi": "10.1101/2020.04.03.023846", "authors": "Franck\u00a0Touret,\u00a0Magali\u00a0Gilles,\u00a0Karine\u00a0Barral,\u00a0Antoine\u00a0Nougair\u00e8de,\u00a0Etienne\u00a0Decroly,\u00a0Xavier\u00a0de Lamballerie,\u00a0Bruno\u00a0Coutard"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4303101", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "To identify possible candidates for progression towards clinical studies against SARS-CoV-2, we screened a well-defined collection of 5632 compounds including 3488 compounds which have undergone clinical investigations (marketed drugs, phases 1 -3, and withdrawn) across 600 indications. Compounds were screened for their inhibition of viral induced cytotoxicity using the human epithelial colorectal adenocarcinoma cell line Caco-2 and a SARS-CoV-2 isolate. The primary screen of 5632 compounds gave 271 hits. A total of 64 compounds with IC50 <20 \u00b5M were identified, including 19 compounds with IC50 < 1 \u00b5M. Of this confirmed hit population, 90% have not yet been previously reported as active against SARS-CoV-2 in-vitro cell assays. Some 37 of the actives are launched drugs, 19 are in phases 1-3 and 10 pre-clinical. Several inhibitors were associated with modulation of host pathways including kinase signaling P53 activation, ubiquitin pathways and PDE activity modulation, with long chain acyl transferases were effective viral inhibitors.", "title": "Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4303101", "journal_full_title": null, "_metadata": {"related_activities": {"count": 5833}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 5618}, "related_targets": {"count": 3}}, "doi": "10.21203/rs.3.rs-23951/v1", "authors": "Bernhard Ellinger,\u00a0Denisa Bojkova,\u00a0Andrea Zaliani,\u00a0Jindrich Cinatl,\u00a0Carsten Claussen,\u00a0Sandra Westhaus,\u00a0Jeanette Reinshagen,\u00a0Maria Kuzikov,\u00a0Markus Wolf,\u00a0Gerd Geisslinger,\u00a0Philip Gribbon,\u00a0Sandra Ciesek"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4303121", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "Rapidly spreading viral pandemics, such as those caused by influenza and SAR-CoV-2 (COVID19), require rapid action and the fastest way to combat this challenge is by repurposing existing drugs as anti-viral therapeutics. Here we first show that human organ-on-a-chip (Organ Chip) microfluidic culture devices lined by a highly differentiated, primary, human lung airway epithelium cultured under an air-liquid interface and fed by continuous medium flow can be used to model virus entry, replication, strain-dependent virulence, host cytokine production, and recruitment of circulating immune cells in response to infection by influenza, as well as effects of existing and novel therapeutics. These Airway Chips, which contain human lung epithelial cells that express high levels of ACE2 and TMPRSS2, were then used to assess the inhibitory activities of 7 clinically approved drugs (chloroquine, arbidol, toremifene, clomiphene, amodiaquine, verapamil, and amiodarone) that we found inhibit infection by viral pseudoparticles expressing SARS-CoV-2 spike protein in human Huh-7 cells, and others recently showed suppress infection by native SARS-CoV-2 in Vero cells. However, when these drugs were administered under flow at the maximal concentration in blood reported in clinical studies in human Airway Chips, only two of these drugs \uf8e7 amodiaquine and toremifene \uf8e7 significantly inhibited entry of the pseudotyped SARS-CoV-2 virus. This work suggests that human Organ Chip technology may be used in conjunction with existing rapid cell-based screening assays to study human disease pathogenesis and expedite drug repurposing in biothreat crises caused by pandemic viruses.", "title": "Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4303121", "journal_full_title": null, "_metadata": {"related_activities": {"count": 35}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 7}, "related_targets": {"count": 2}}, "doi": "10.1101/2020.04.13.039917", "authors": "Longlong Si, Haiqing Bai, Melissa Rodas, Wuji Cao, Crystal Yuri Oh, Amanda Jiang, Atiq Nurani, Danni Y. Zhu, Girija Goyal, Sarah E. Gilpin, Rachelle Prantil- Baun, and Donald E. Ingber"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4303773", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 2.3 million people, killed over 160,000, and caused worldwide social and economic disruption1,2. There are currently no antiviral drugs with proven clinical efficacy, nor are there vaccines for its prevention, and these efforts are hampered by limited knowledge of the molecular details of SARS-CoV-2 infection. To address this, we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), identifying 332 high-confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 66 druggable human proteins or host factors targeted by 69 compounds (29 FDA-approved drugs, 12 drugs in clinical trials, and 28 preclinical compounds). Screening a subset of these in multiple viral assays identified two sets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the Sigma1 and Sigma2 receptors. Further studies of these host factor targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.", "title": "A SARS-CoV-2 protein interaction map reveals targets for drug repurposing", "volume": null, "pubmed_id": 32353859, "first_page": null, "document_chembl_id": "CHEMBL4303773", "journal_full_title": "Nature.", "_metadata": {"related_activities": {"count": 410}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 77}, "related_targets": {"count": 14}}, "doi": "10.1038/s41586-020-2286-9", "authors": "David E Gordon, Gwendolyn M Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Kris M White, Matthew J O'Meara, Veronica V Rezelj, Jeffrey Z Guo, Danielle L Swaney, et al"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4303082", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "The emergence of novel SARS coronavirus 2 (SARS-CoV-2) in 2019 has triggered an ongoing global pandemic of severe pneumonia-like disease designated as coronavirus disease 2019 (COVID-19). To date, more than 2.1 million confirmed cases and 139,500 deaths have been reported worldwide, and there are currently no medical countermeasures available to prevent or treat the disease. As the development of a vaccine could require at least 12-18 months, and the typical timeline from hit finding to drug registration of an antiviral is >10 years, repositioning of known drugs can significantly accelerate the development and deployment of therapies for COVID-19. To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, we profiled a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules. Here, we report the identification of 30 known drugs that inhibit viral replication. Of these, six were characterized for cellular dose-activity relationships, and showed effective concentrations likely to be commensurate with therapeutic doses in patients. These include the PIKfyve kinase inhibitor Apilimod, cysteine protease inhibitors MDL-28170, Z LVG CHN2, VBY-825, and ONO 5334, and the CCR1 antagonist MLN-3897. Since many of these molecules have advanced into the clinic, the known pharmacological and human safety profiles of these compounds will accelerate their preclinical and clinical evaluation for COVID-19 treatment.", "title": "A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4303082", "journal_full_title": null, "_metadata": {"related_activities": {"count": 18}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 18}, "related_targets": {"count": 1}}, "doi": "10.1101/2020.04.16.044016", "authors": "Laura\u00a0Riva,\u00a0Shuofeng\u00a0Yuan,\u00a0Xin\u00a0Yin,\u00a0Laura\u00a0Martin-Sancho,\u00a0Naoko\u00a0Matsunaga,\u00a0Sebastian\u00a0Burgstaller-Muehlbacher,\u00a0Lars\u00a0Pache,\u00a0Paul P.\u00a0De Jesus,\u00a0Mitchell V.\u00a0Hull,\u00a0Max\u00a0Chang,\u00a0Jasper Fuk-Woo\u00a0Chan,\u00a0Jianli\u00a0Cao,\u00a0Vincent Kwok-Man\u00a0Poon,\u00a0Kristina\u00a0Herbert,\u00a0Tu-Trinh\u00a0Nguyen,\u00a0Yuan\u00a0Pu,\u00a0Courtney\u00a0Nguyen,\u00a0Andrey\u00a0Rubanov,\u00a0Luis\u00a0Martinez-Sobrido,\u00a0Wen-Chun\u00a0Liu,\u00a0Lisa\u00a0Miorin,\u00a0Kris M.\u00a0White,\u00a0Jeffrey R.\u00a0Johnson,\u00a0Christopher\u00a0Benner,\u00a0Ren\u00a0Sun,\u00a0Peter G.\u00a0Schultz,\u00a0Andrew\u00a0Su,\u00a0Adolfo\u00a0Garcia-Sastre,\u00a0Arnab K.\u00a0Chatterjee,\u00a0Kwok-Yung\u00a0Yuen,\u00a0Sumit K.\u00a0Chanda"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4303084", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "COVID-19 is an emerging infectious disease and was recently declared as a pandemic by WHO. Currently, there is no vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of 48 FDA- approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 \u03bcM < IC50 < 10 \u03bcM) against SARS-CoV-2. In particular, two FDA-approved drugs - niclosamide and ciclesonide \u2013 were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.", "title": "Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4303084", "journal_full_title": null, "_metadata": {"related_activities": {"count": 144}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 48}, "related_targets": {"count": 3}}, "doi": "10.1101/2020.03.20.999730", "authors": "Sangeun Jeon, Meehyun Ko, Jihye Lee, Inhee Choi, Soo Young Byun, Soonju Park, David Shum, Seungtaek Kim"}}, {"_index": "chembl_28_document", "_type": "_doc", "_id": "CHEMBL4303122", "_score": 8.853835, "_source": {"patent_id": null, "src_id": 52, "issue": null, "year": 2020, "last_page": null, "abstract": "To identify potential therapeutic stop-gaps for SARS-CoV-2, we evaluated a library of 1,670 approved and reference compounds in an unbiased, cellular image-based screen for their ability to suppress the broad impacts of the SARS-CoV-2 virus on phenomic profiles of human renal cortical epithelial cells using deep learning. In our assay, remdesivir is the only antiviral tested with strong efficacy, neither chloroquine nor hydroxychloroquine have any beneficial effect in this human cell model, and a small number of compounds not currently being pursued clinically for SARS-CoV-2 have efficacy. We observed weak but beneficial class effects of beta-blockers, mTOR/PI3K inhibitors and Vitamin D analogues and a mild amplification of the viral phenotype with beta-agonists.", "title": "Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2", "volume": null, "pubmed_id": null, "first_page": null, "document_chembl_id": "CHEMBL4303122", "journal_full_title": null, "_metadata": {"related_activities": {"count": 1669}, "source": [{"src_description": "SARS-CoV-2 Screening Data", "src_id": 52, "src_short_name": "SARS_COV_2"}], "related_compounds": {"count": 1629}, "related_targets": {"count": 1}}, "doi": "10.1101/2020.04.21.054387", "authors": "Katie Heiser, Peter F. McLean, Chadwick T. Davis, Ben Fogelson, Hannah B. Gordon, Pamela Jacobson, Brett Hurst, Ben Miller, Ronald W. Alfa, Berton A. Earnshaw, Mason L. Victors, Yolanda T. Chong, Imran S. Haque, Adeline S. Low, Christopher C. Gibson"}}]